ライフサイエンスコーパス: median

1 daily FA intake was dichotomized at 800mug (median).

2 9.5), second (median, 3.5 vs 9), and third (median, 0 vs 10.5) assessments (all p < 0.001).

3 th delirium than those without at the first (median, 0 vs 9.5), second (median, 3.5 vs 9), and third

4 compared with none ranged from 0.26 to 3.48 (median, 0.74), from 0.48 to 11.04 (median, 1.95), and fr

5 hildren who died or were delisted received a median 1 pediatric liver offer and waited a median of 33

6 up had a mean 1.8 (95% CI, 1.7 to 2.0) and a median 1.7 (IQR, 1.0-2.0) pulmonary complications score

7 11.04 (median, 1.95), and from 0.48 to 5.17 (median, 1.30), respectively.

8 to 3.48 (median, 0.74), from 0.48 to 11.04 (median, 1.95), and from 0.48 to 5.17 (median, 1.30), res

9 5.0 cell layers to surface; IQR, 2.5-9.3 vs median 10.4 cell layers to surface; IQR, 8.0-16.9; P = .

10 tween patients with a diagnosis of dementia (median, 11.5 microg/L; interquartile range, 6.5-14.9 mic

11 METHODS AND Twenty-five patients aged median 12.0 years after repair of tetralogy of Fallot an

12 The mean largest basal diameter was 11 mm (median, 12 mm; range, 3-24 mm), and mean thickness was 5

13 tile range, 6.5-14.9 microg/L) and controls (median, 12.2 microg/L; interquartile range, 7.3-16.0 mic

14 sition from disease progression to recovery (median 16% per year, 95% uncertainty range 11%-21%).

15 of partners in the past 5 years was greater (median 2 [IQR 1-4] for black Caribbean and 2 [1-5] for b

16 A total of 50 carousels were identified (median 2; quartiles 1-3 per map), although this represen

17 diagnosis was 2.8 (standard deviation, 2.5) (median, 2.0; interquartile range, 1.0-4.0).

18 ean duration of chemotherapy was 2.3 months (median, 2.1 months).

19 tes and two interstitial 5S sites, while the median (2n = 24) presents four terminal 35S sites and th

20 ongoing, and each had 2-16 assessment waves (median = 3) and a follow-up duration of 2-15 y.

21 (median, 6 d), and midterm after PVR (mPVR; median, 3 y).

22 posity in 1,006 children in early childhood (median, 3.2 years) and 876 in mid-childhood (median, 7.7

23 out at the first (median, 0 vs 9.5), second (median, 3.5 vs 9), and third (median, 0 vs 10.5) assessm

24 across the 306 US hospital referral regions (median = 33%, interquartile range = 17%-49%).

25 lus docetaxel versus placebo plus docetaxel (median 4.07 months [95% CI 2.96-4.47] vs 2.76 months [2.

26 13 subjects resulted in rapid defervescence (median, 4 hr) and clinical improvement.

27 ange, 3-24 mm), and mean thickness was 5 mm (median, 4 mm; range, 1-20 mm).

28 Load was higher in MCPP cases than controls (median, 4.0 x 103 vs 0.19 x 103 copies/mL), but overlapp

29 0001 vs ERD, BE, and controls) and proximal (median, 5.0 cell layers to surface; IQR, 2.5-9.3 vs medi

30 were followed up for as long as 10.7 years (median, 5.5 years).

31 ation rates (mL/min per 1.73 m) of 43 to 72 (median, 55).

32 ed before PVR (pPVR), immediately after PVR (median, 6 d), and midterm after PVR (mPVR; median, 3 y).

33 ision of OSSN and onset of LSCD was 8 weeks (median, 6 weeks; range, 6-12 weeks).

34 s) in the study, during 485322 person-years (median, 6.7 years) of observation, 5750 (8.4%) sustained

35 median, 3.2 years) and 876 in mid-childhood (median, 7.7 years) using anthropometric and dual X-ray a

36 3, 23.05% vs 23.7%; P > .99), hospital stay (median: 8 vs 8.5 days; P = .31), 30-day readmission (22.

37 mucosa from patients with NERD-both distal (median, 9.5 cell layers to surface; IQR, 1.5-13.3; P < .

38 A methylation at 329 unique CpG sites, has a median absolute error of 3.33 weeks and has similar prop

39 was measured in contrast SB series (n = 169, median age 0.94, range 0.32-2.7 years) during 2002 to 20

40 er 87 months were included; 68% were female, median age 46 (range, 11-88 years), and median presentin

41 nrolled and all patients received treatment; median age 68 years.

42 We compared the median age at cancer diagnosis between PLWH in the North

43 METHODS AND We included 3311 adults (median age at entry 22.6 years, 50.6% males) with CHD (4

44 Median age at genetic evaluation was 11 years; 20.7% of

45 Median age at referral was similar for men (22.5 years;

46 The median age at TA diagnosis was 36 [25-47] years, and 276

47 We included 9 eyes; median age at the moment of the PPK was 14 years.

48 The median age in the MFS group was 35.4 years versus 35.6 y

49 418 children (693 girls and 725 boys) with a median age of 27 months (interquartile range, 12-69 mont

50 otal of 220 children (147 boys [67%]) with a median age of 5.0 months (interquartile range, 3.0-8.0 m

51 Sixty-three patients with a median age of 73 y who underwent 307 cycles of therapy w

52 The median age of participants was 86 years (range, 48-96 ye

53 The median age of the 1005 enrolled infants was 3 months (in

54 ears) is projected at 33.5% in 2030, and the median age of the NAFLD population will increase from 50

55 The median age of the patients was 53 years (range 37-64).

56 The median age of the patients was 66 years, and 72% were me

57 Median age of the study cohort was 46 (interquartile ran

58 Median age was 36 years, 48% of participants were women,

59 Median age was 41 years (interquartile range: 27 to 53 y

60 Median age was 43 years, 88% were black, 73% male, 69% h

61 Of 863 patients, 551 (63.9%) were male and median age was 58 years (interquartile range, 51-68 year

62 In these patients, median age was 58 years (IQR 51-62), median number of pr

63 The median age was 67 years, and the median PSA level was 53

64 nts with CRKP colonization or infection, the median age was 73 years.

65 Median age was 77 years (range 62-92), and median follow

66 The median age was 78 years, and 73% (35/48) were male.

67 Among 3886 women (median age, 38 years; interquartile range [IQR], 30-46 y

68 for the breast cancer analysis, 5066 women (median age, 38 years; IQR, 31-47 years) eligible for the

69 In the 16 patients (6 men and 10 women; median age, 42 [range, 18-69] years), clinical improveme

70 patients were identified (female, 42 [80%]; median age, 44 years; age range, 13-82 years).

71 the ovarian cancer analysis, and 2213 women (median age, 47 years; IQR, 40-55 years) eligible for the

72 vational studies), involving 62068 patients (median age, 58.8 years; median APACHE [Acute Physiology

73 spective analysis of 92 patients with HGSOC (median age, 61 years) with abdominopelvic CT before prim

74 ed stopping the study for futility when 894 (median age, 63 years; 286 [32%] women) of the planned 11

75 selected patients with and without delirium (median age, 63 yr; range, 23-84) who were assessed with

76 A total of 298 patients were accrued (median age, 68.8 [range, 32-94] years at day 10 and 68.0

77 were 1293 men (61.8%) and 800 women (38.2%) (median age, 73 years).

78 Of 111 patients included (67 [60%] male; median age, 75 [range, 24-94] years), 81 (73%) were emer

79 The medians and 95th percentiles for the time until the loss

80 roups with longer and shorter distances than median, and larger and smaller angles than median betwee

81 were expressed in the brain above the array median, and remained significantly associated with relev

82 e survey datapoints, the population-weighted median annual rate of change of catastrophic payment inc

83 ving 62068 patients (median age, 58.8 years; median APACHE [Acute Physiology and Chronic Health Evalu

84 For some of the used devices the median ARD was even well below 10%.

85 mean age of 66 years, 73% were male, and the median baseline ankle-brachial index was 0.78.

86 pants with a positive result in phase 1, the median baseline cycle-threshold values (higher values in

87 Median best-corrected visual acuity (BCVA) was 20/30 at

88 n median, and larger and smaller angles than median between NBSL and fixation.

89 The median birthweight was 3,300 g (IQR 2,980-3,615).

90 Median cancer-related survival was 37.7 months (confiden

91 ow was significantly more restrictive (lower median CCS) in the hemorrhagic group than in the nonhemo

92 Sixty patients were included (median CD4 count 53 cells/microL (interquartile range [I

93 In intention-to-treat analysis, the median CFT change showed no significant difference.

94 Median change in successfully consumed doses were 0, 43,

95 Median cigarette prices and the differential between the

96 pectively, which is 30 to 50% lower than the median concentrations in residential indoor air.

97 The patients' median COPPS was 8.9 points (range, 5-14).

98 inpatient admission, with 23% lower relative median costs, 0.77 (0.69-0.87).

99 The median delay from neurological symptom debut to first ho

100 the depth of impoverishment but focus on the median depth for the 122 countries in our sample, accoun

101 p = 0.31), whereas those with SPRM above the median derived the greatest benefit (adjusted HR: 0.599;

102 ase from 14.9 to 14.1 with placebo (adjusted median difference between the cannabidiol group and the

103 cer than those with nontruncating mutations (median difference, 6.6 years; 95% CI, 2.7-10.4; P = .002

104 f mice received the radiopharmaceutical in a median dose of either 165 MBq (129-232 MBq, n = 10) or 1

105 tent with slow rates of disease progression (median doubling time: 84 days, 95% uncertainty range 62-

106 induced CytoRS-AEs (most commonly headache, median duration <1 day) in 93% of participants at 80 ng,

107 The median duration of treatment for the 204 patients was 5.

108 magnitude antibody levels than adults (gp120 median FIs of 15,509 [infants] and 2,290 [adults], P < 0

109 infants] and 2,290 [adults], P < 0.001; V1V2 median FIs of 23,926 [infants] and 1,538 [adults]; P < 0

110 unized with the alum/MNrgp120 vaccine (gp120 median fluorescence intensities [FIs] in infants = 7,118

111 ants and tested 130 seminal fluid specimens; median follow up was 197 days (IQR 187-209 days) after e

112 Median follow-up after transplantation was 6.6 years (37

113 Median follow-up at the end of the trial on Nov 5, 2014,

114 At the data cutoff, median follow-up duration was 11.0 months (range, 1.3 to

115 Median time to recurrence was 14 months, and median follow-up for control subjects was 102 months.

116 nts were followed from 1985 to 2009, and the median follow-up from baseline to CRC diagnosis was 8.2

117 At a median follow-up of 12.0 months (IQR 8.6-18.0), 23 (31.1

118 After a median follow-up of 13 years, 1 or more ODHs were detect

119 At median follow-up of 15.6 months, progression-free surviv

120 At the latest median follow-up of 19 months, there was 100% (death-cen

121 Among HF cases, 952 deaths occurred over a median follow-up of 2.3 years.

122 Two hundred ninety-seven eyes with a median follow-up of 2.6 years were included.

123 At a median follow-up of 2.8 years (range, 0.03-12.8 years),

124 , or unstable angina hospitalizations over a median follow-up of 26.1 months.

125 During a median follow-up of 27 months (IQR: 6 to 62 months), 50%

126 At a median follow-up of 36 months, the study reveals no diff

127 Over a median follow-up of 4.0 years, 340 participants died.

128 During a median follow-up of 5.0 years (interquartile range, 3.5-

129 During a median follow-up of 6.8 years, 256 recipients died, 35 (

130 vived (estimated survival 57 +/- 13%) with a median follow-up of 65 months (minimum 38 months).

131 included for analysis, 1600 died during the median follow-up of 7.1 years.

132 Results At a median follow-up of 7.4 years, addition of rituximab to

133 After a median follow-up of 79 months, 86 patients had discontin

134 mean eGFR was 94 ml/min per 1.73 m(2) Over a median follow-up of 8 years, 228 (6.4%) cases of inciden

135 The median follow-up time was 4.8 years.

136 The median follow-up time was 82 months (range, 6-329 months

137 Median follow-up was 1.7 months (IQR 1.4-4.1).

138 Median follow-up was 15.9 months (IQR 7.8-22.0) at the d

139 Median follow-up was 173 days (interquartile range: 54 t

140 Median follow-up was 23.2 months (IQR 14.8-28.7).

141 Median follow-up was 28.0 months (IQR 14.6-36.6).

142 follow-up duration was up to 7.9 years, and median follow-up was 3.1 years.

143 The median follow-up was 40 months.

144 Median follow-up was 43 months (interquartile range 35-4

145 Median follow-up was 8.6 (range, 0.2-37) years.

146 At the time of analysis, the median follow-up was 84 months (range, 1 to 119 months).

147 Median follow-up was 9.1 years (range 5.1 -21.2 yrs).

148 Median age was 77 years (range 62-92), and median follow-up was 953 days (IQR 721-1040).

149 In HD8 (N = 1,064; median follow-up, 153 months), noninferiority of involve

150 In HD10 (N = 1,190; median follow-up, 98 months), noninferiority of two cycl

151 The median frequency of convulsive seizures per month decrea

152 The median frequency of latently infected rCD4 cells in this

153 The median FTOH concentrations observed in personal air were

154 Median gestational age of CCC infants was 26 3/7 (range,

155 PRM-predicted risk of sudden death below the median had no reduction in mortality with the ICD (adjus

156 Median IC densities were not significantly decreased in

157 Median in-hospital CCI was comparable for both groups (D

158 Median intakes of 1.7, 0.17, 5.7, 0.57, 1.8, 0.18, and 2

159 Our 300-patient cohort had a median (interquartile range) age of 20 months (11-37 mo)

160 The median (interquartile range) follow-up time was 9.1 (5.1

161 ren (712 boys [52.0%] and 657 girls [48.0%]; median [interquartile range] age, 12.9 [11.2-15.3]), of

162 sidents were older than immigrant decedents (median [interquartile range] age, 75 [58-84] vs 80 [68-8

163 n for all subjects was 27.7 +/- 18.9 nmol/L [median (IQR): 23.5 nmol/L (13.3, 37.3 nmol/L)] and showe

164 s 5.2 months (95% CI, 3.2 to 7.1 months) and median ITT overall survival, 9.5 months (95% CI, 5.9 to

165 Median ITT progression-free survival was 5.2 months (95%

166 f 55 patients with OA-MCL were reviewed; the median length of follow-up was 33 months.

167 Median length of stay was 4 days (range 2 to 6 days).

168 bsequent adult environment, more than double median lifespan.

169 ovir vs cidofovir; CR = 13 (80%) vs 8 (35%); median lymphocyte count = 320/mul vs 910/mul; P < .05).

170 Median M-score for complicated cases was higher (P = .02

171 MELD scores >/=35 who were transplanted at a median MELD score of 39 (interquartile range [IQR] 37-40

172 ,118 and in adults = 11,510, P = 0.070; V1V2 median MFIs of 512 [infants] and 804 [adults], P = 0.50)

173 Results The median MHD was 2.37 Gy (range, 0.51 to 15.25 Gy).

174 -5 to -3.6) with sevoflurane delivered at a median minimum alveolar concentration of 0.45% (interqua

175 exon 11 deletion mutations, higher-than-the-median mitotic counts were associated with unfavorable R

176 h Heart Failure score (48 versus 40), higher median N-terminal pro-B-type natriuretic peptide concent

177 n did those who were not on anticoagulation (median National Institutes of Health Stroke Scale 12, 13

178 ure at local versus distal sites may improve median nerve function at the wrist by somatotopically di

179 re disease limited to the liver and a higher median number of cycles (close to 12).

180 ions over the course of clinical management (median number of OCT scans per eye, 5; range, 1-15).

181 ally actionable alteration (94.7%), with the median number of potentially actionable alterations per

182 tients, median age was 58 years (IQR 51-62), median number of previous lines of therapy was two (2-5)

183 ean (SD) age, 9.9 [1.5] years), the adjusted median number of trigger pulls among children who saw th

184 Median observation time was 12.9 years from primary diag

185 CD4 count decreased by a median of -130 cells per muL (range -472 to 266) with li

186 ntly transmitted pressure information with a median of 1.27 days between transmissions after 6 months

187 mmune response, despite patients receiving a median of 10 doses.

188 Results After a median of 10.8 years of follow-up since diagnosis, 381 d

189 e estimated prevalence of VAD decreased by a median of 11-18 percentage points in PSC compared with u

190 range [IQR], 22-132); 16 (27%) died after a median of 12 (IQR, 0-24) days.

191 ting symptoms compatible with heart failure (median of 13 [range 0-76] in the Minnesota Living with H

192 ICU admission occurred at a median of 146 (interquartile range, 27-321) days after a

193 ients had been enrolled with follow-up for a median of 15 months.

194 or 4.7 +/- 1.9 years, 753 (20%) had IBx at a median of 15.3 months posttransplant.

195 eviewed articles have been published after a median of 19 months (9-32 months) from the data-sharing

196 rium was diagnosed in 267 (17%) and lasted a median of 2 days (interquartile range, 1-5).

197 tic disease on statin therapy followed for a median of 2.2 years.

198 In a median of 2.5 years (mean: 7.7 years) from the subconjun

199 Results A total of 99 nodules measuring a median of 20 mm (range, 5-47 mm) in lung window CT image

200 A median of 3 antigenic regions were targeted with a highe

201 median 1 pediatric liver offer and waited a median of 33 days.

202 During a median of 4.1 years, surgery patients had lower heart fa

203 t of 10 stable kidney transplant recipients (median of 4.3 years posttransplantation) with late activ

204 pies herpes simplex virus DNA/ml collected a median of 5 months apart (IQR: 2-11 months) were include

205 ecurrent CMV occurred in 30.5% patients at a median of 51 (0-160) days after discontinuation of thera

206 .5%) virologic failures resuppressed after a median of 8.0 months (interquartile range, 2.8-16.8 mont

207 There were 367 recipients followed up for a median of 9.7 years between 1990 and 2012, with 82 (22%)

208 ults Eighty-six patients who had undergone a median of five prior therapies (range, one to 13) were e

209 n and mothers in 32 Ugandan households for a median of one year.

210 Median of the maximum declines in HIV-1 RNA were similar

211 Patients received a median of two (IQR 1-2) previous therapies.

212 gested that, in gestational weeks 32-39, the median or geometric mean SF concentrations were 6-21 mug

213 lic disease or progressive disease) showed a median OS of 4.4 mo (1-y and 2-y OS was 33% and 0%, resp

214 Median OS was found to be inferior in the DPL arm compar

215 The median overall survival (OS) was 30 months (95% confiden

216 The unadjusted median overall survival by facility volume was: Q1: 26.9

217 The median overall survival duration was significantly longe

218 Median overall survival from the start of chemotherapy w

219 d with atezolizumab compared with docetaxel (median overall survival was 13.8 months [95% CI 11.8-15.

220 val was 6.0 (95% CI, 5.0 to 7.3) months, and median overall survival was 16.6 (95% CI, 11.1 to 20.6)

221 Median overall survival was not reached for treated pati

222 using point estimates for weighted values of median overall survival, progression-free survival, resp

223 The median parasite clearance time was 24 hours in both the

224 Median patient DOTs in the PPA and PPRF arms were 8 and

225 on stores increased by 7-25 and 2-8 absolute median percentage points for PSC and WRA, respectively,

226 Results Median PFS and OS were significantly shorter in women wi

227 0.640 (95% CI, 0.462-0.888; P = .007), with median PFS of 20.6 vs 15.6 months.

228 interval [CI], 0.321-0.918; P = .021), with median PFS of 21.4 vs 9.7 months; in standard-risk patie

229 consecutive days of ibrutinib had a shorter median PFS vs those missing <8 days (10.9 months vs not

230 Median PFS was 4.4 months with C20, 5.1 months with C25,

231 The median PFS was 52.8 months for the lenalidomide group an

232 pre-existing midline, and the dorsal-ventral median plane.

233 g data from an influential study reporting a median power of 21% across 49 meta-analyses.

234 Stimulation of glutamatergic median preoptic area neurons produced a profound hypothe

235 sculosum of the lamina terminalis (OVLT) and median preoptic nucleus (MnPO).

236 ale, median age 46 (range, 11-88 years), and median presenting ADAMTS13 of <5% (range, <5%-18%).

237 The median previous lines of therapy was 6 (range, 3-13).

238 there been no cost differential between the median-priced and minimum-priced cigarettes during this

239 7.5% with a complete response rate of 12.5%, median progression-free survival (PFS) of 14 months, and

240 In total, 27 patients with liposarcoma had a median progression-free survival of 237 days.

241 Median progression-free survival was 2.8 months (95% CI

242 Median progression-free survival was 6.0 (95% CI, 5.0 to

243 In PI3K pathway-activated patients (n=372), median progression-free survival was 6.8 months (95% CI

244 Median progression-free survival was significantly impro

245 Median progression-free survival was significantly longe

246 The median age was 67 years, and the median PSA level was 53 ng per milliliter.

247 Median (range) follow-up in 68 adults (median [range] ag

248 A total of 5626 patients (86.0% male; median [range] age, 58 [21-90] years) were identified.

249 atients with mild to moderate CKD (42 women; median [range] age, 65 [23-78] years).

250 atients were randomized to the rotating arm (median [range] age, 65 [44-87] years) and 49 patients to

251 Median (range) follow-up in 68 adults (median [range] age, 66 [48-83] years; 19% female) was 38

252 ] years) and 49 patients to the control arm (median [range] age, 67 [38-82] years).

253 The median RD border displacement velocity was +1 mum/hour (

254 Median relapse-free survival and overall survival were 6

255 h fasting glucose levels below and above the median, respectively.

256 egions were targeted with a higher-magnitude median response to Gagp24 regions, more conserved betwee

257 Median Richmond Agitation Sedation Scale was -4.5 (inter

258 were similar for patients below or above the median risk (0.77 vs 0.75; P = .92).

259 Median risk estimates from Monte Carlo simulations range

260 n the Kidney Disease Quality of Life Survey (median score, 0 in the sertraline group vs 0 in the plac

261 Median serum copper level was 0.11 mug/mL (range 0-0.58)

262 okines, CCL2 and CXCL10, correlated with the median stimulus length in the 5-CSRTT.

263 The median survival for SCLC remained 7 months, and the 12-m

264 rutinib for up to 3 months, with 19.8 months median survival from the time of progression.

265 The median survival is only 5 mo, and the 1-y survival is le

266 scharge after OHCA treated with PAD showed a median survival of 40.0% (range, 9.1-83.3).

267 r differentiation according to difference in median survival time between high- and low-risk groups (

268 l subtype who underwent trimodality therapy, median survival was extended from 14.5 months to 23.4 mo

269 prostate DKO) exhibited a markedly increased median survival with reduced tumor size and proliferatio

270 The median SUVmax of 94 tumor lesions was 7.3 (range, 1.6-59

271 After 2 wk, median SUVmax was 6.3 (1.7-62.3), corresponding to a mea

272 0.73-1.16, p = 0.49) when compared with the median tertile.

273 Mean and median TF levels were 72.5 pg/mL and 50.3 pg/mL, respect

274 01) and to have a thinner invasive melanoma (median thickness, 0.37 mm vs 0.65 mm; P < .001).

275 The median time between invitations (2.37 years) was used as

276 death for each type of synucleinopathy, the median time from diagnosis to death, and the causes of d

277 an age, 44 years [SD, 15]; women, 274 [57%]; median time from orthopedic implant placement, 11 months

278 The median time from palliative care consultation to death w

279 PSC door in to door out that reduced from a median time of 104 minutes (95% CI, 82-112 minutes) to a

280 te in 61.5% of patients and occurred after a median time of 3 hours after extracorporeal life support

281 Cryptosporidiosis occurred at a median time of 3.4 (0-19.8) years posttransplant.

282 of 104 minutes (95% CI, 82-112 minutes) to a median time of 64 minutes (95% CI, 51-71.0 minutes) (P <

283 The median time of day for extubation with an extubation rea

284 Median time of death for patients with FMF was 61 months

285 Serum samples were collected over a median time period of 10 years and analyzed for antibodi

286 Teledermatology reduced median time to evaluation from 70.0 days (interquartile

287 Median time to fixation was 15 hours (IQR 7-24 hours) an

288 Median time to progression and duration of response were

289 Median time to recurrence was 14 months, and median foll

290 Median time to transplantation for such patients is doub

291 days) to 0.5 days (IQR, 0.172-0.94 days) and median time to treatment from 73.5 to 3.0 days compared

292 ed after hospital discharge, with a 19.5-day median time to VTE.

293 The median total household income for the study sample was 8

294 Strikingly, we find a median value of 5 TBP-chromatin binding events associat

295 nations (analyzed by using SAS 9.3) provided median values, as well as means and 25th and 75th (DRL)

296 nd among all types of oils, with the highest median values.

297 The median ventricular arrhythmia score during exercise was

298 Patients with CMV pneumonia had higher median viral loads (3.9 log10 IU/mL; interquartile range

299 presented by 3416 individuals in NHANES, the median weighted age was 53 years (interquartile range, 4

300 clinical series (11 out of 15 studies with a median year since 2007) are higher than the true LNP pro